BTIG analyst Justin Zelin assumed coverage of Lyra Therapeutics with a Buy rating and $15 price target. The analyst sees an attractive opportunity for Lyra to address the 4M chronic rhinosinusitis patients that are not addressed by available therapies in the pre- and post-surgery settings with the company’s next-generation steroid eluting implants LYR-210 and 220. The firm sees Lyra as an “underappreciated company with viable differentiated products” that address unmet needs in a large chronic rhinosinusitis market.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LYRA:
- Lyra Therapeutics price target raised to $15 from $13 at BofA
- Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery
- Lyra Therapeutics announces results from BEACON Phase 2 study of LYR-220
- Lyra Therapeutics to Participate in Upcoming Investor Conferences
- Lyra Therapeutics initiated with a Buy at H.C. Wainwright
